Description of 3 patients with myasthenia gravis and COVID-19.
Identifieur interne : 000677 ( Main/Exploration ); précédent : 000676; suivant : 000678Description of 3 patients with myasthenia gravis and COVID-19.
Auteurs : Netaniel Rein [Israël] ; Nitzan Haham [Israël] ; Efrat Orenbuch-Harroch [Israël] ; Marc Romain [Israël] ; Zohar Argov [Israël] ; Adi Vaknin-Dembinsky [Israël] ; Marc Gotkine [Israël]Source :
- Journal of the neurological sciences [ 1878-5883 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Azithromycine (usage thérapeutique), Betacoronavirus (MeSH), Diabète de type 2 (complications), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Hypertension artérielle (complications), Hypothyroïdie (complications), Immunoglobulines par voie veineuse (usage thérapeutique), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Infections à coronavirus (complications), Infections à coronavirus (traitement médicamenteux), Lopinavir (usage thérapeutique), Myasthénie (complications), Myasthénie (thérapie), Myasthénie (traitement médicamenteux), Mâle (MeSH), Pandémies (MeSH), Plasmaphérèse (MeSH), Pneumopathie virale (complications), Pneumopathie virale (traitement médicamenteux), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Sujet immunodéprimé (MeSH), Sujet âgé (MeSH).
- MESH :
- effets indésirables : Diabète de type 2, Hypertension artérielle, Hypothyroïdie, Immunosuppresseurs, Infections à coronavirus, Myasthénie, Pneumopathie virale.
- thérapie : Myasthénie.
- traitement médicamenteux : Infections à coronavirus, Myasthénie, Pneumopathie virale.
- usage thérapeutique : Azithromycine, Hydroxychloroquine, Immunoglobulines par voie veineuse, Immunosuppresseurs, Lopinavir, Ritonavir.
- Adulte, Betacoronavirus, Femelle, Humains, Mâle, Pandémies, Plasmaphérèse, Résultat thérapeutique, Sujet immunodéprimé, Sujet âgé.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Azithromycin (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Diabetes Mellitus, Type 2 (complications), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Hypertension (complications), Hypothyroidism (complications), Immunocompromised Host (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Lopinavir (therapeutic use), Male (MeSH), Myasthenia Gravis (complications), Myasthenia Gravis (drug therapy), Myasthenia Gravis (therapy), Pandemics (MeSH), Plasmapheresis (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Ritonavir (therapeutic use), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , therapeutic use : Azithromycin, Hydroxychloroquine, Immunoglobulins, Intravenous, Immunosuppressive Agents, Lopinavir, Ritonavir.
- complications : Coronavirus Infections, Diabetes Mellitus, Type 2, Hypertension, Hypothyroidism, Myasthenia Gravis, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Myasthenia Gravis, Pneumonia, Viral.
- therapy : Myasthenia Gravis.
- Adult, Aged, Betacoronavirus, Female, Humans, Immunocompromised Host, Male, Pandemics, Plasmapheresis, Treatment Outcome.
Abstract
BACKGROUND
The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.
CASE DESCRIPTION
We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.
CONCLUSION
Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
DOI: 10.1016/j.jns.2020.117053
PubMed: 32731059
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Description of 3 patients with myasthenia gravis and COVID-19.</title><author><name sortKey="Rein, Netaniel" sort="Rein, Netaniel" uniqKey="Rein N" first="Netaniel" last="Rein">Netaniel Rein</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Netaniel.rein@mail.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Haham, Nitzan" sort="Haham, Nitzan" uniqKey="Haham N" first="Nitzan" last="Haham">Nitzan Haham</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Nitan.haham@mail.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Orenbuch Harroch, Efrat" sort="Orenbuch Harroch, Efrat" uniqKey="Orenbuch Harroch E" first="Efrat" last="Orenbuch-Harroch">Efrat Orenbuch-Harroch</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Romain, Marc" sort="Romain, Marc" uniqKey="Romain M" first="Marc" last="Romain">Marc Romain</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel. Electronic address: Marcro@hadassah.org.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Argov, Zohar" sort="Argov, Zohar" uniqKey="Argov Z" first="Zohar" last="Argov">Zohar Argov</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: zohara@ekmd.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Vaknin Dembinsky, Adi" sort="Vaknin Dembinsky, Adi" uniqKey="Vaknin Dembinsky A" first="Adi" last="Vaknin-Dembinsky">Adi Vaknin-Dembinsky</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Gotkine, Marc" sort="Gotkine, Marc" uniqKey="Gotkine M" first="Marc" last="Gotkine">Marc Gotkine</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: marc@gotkine.com.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32731059</idno><idno type="pmid">32731059</idno><idno type="doi">10.1016/j.jns.2020.117053</idno><idno type="wicri:Area/Main/Corpus">000917</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000917</idno><idno type="wicri:Area/Main/Curation">000917</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000917</idno><idno type="wicri:Area/Main/Exploration">000917</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Description of 3 patients with myasthenia gravis and COVID-19.</title><author><name sortKey="Rein, Netaniel" sort="Rein, Netaniel" uniqKey="Rein N" first="Netaniel" last="Rein">Netaniel Rein</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Netaniel.rein@mail.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Haham, Nitzan" sort="Haham, Nitzan" uniqKey="Haham N" first="Nitzan" last="Haham">Nitzan Haham</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Nitan.haham@mail.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Orenbuch Harroch, Efrat" sort="Orenbuch Harroch, Efrat" uniqKey="Orenbuch Harroch E" first="Efrat" last="Orenbuch-Harroch">Efrat Orenbuch-Harroch</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Romain, Marc" sort="Romain, Marc" uniqKey="Romain M" first="Marc" last="Romain">Marc Romain</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel. Electronic address: Marcro@hadassah.org.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Argov, Zohar" sort="Argov, Zohar" uniqKey="Argov Z" first="Zohar" last="Argov">Zohar Argov</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: zohara@ekmd.huji.ac.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Vaknin Dembinsky, Adi" sort="Vaknin Dembinsky, Adi" uniqKey="Vaknin Dembinsky A" first="Adi" last="Vaknin-Dembinsky">Adi Vaknin-Dembinsky</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Gotkine, Marc" sort="Gotkine, Marc" uniqKey="Gotkine M" first="Marc" last="Gotkine">Marc Gotkine</name><affiliation wicri:level="1"><nlm:affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: marc@gotkine.com.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:regionArea><wicri:noRegion>the Agnes-Ginges Center for Neurogenetics Jerusalem</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of the neurological sciences</title><idno type="eISSN">1878-5883</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Hypertension (complications)</term><term>Hypothyroidism (complications)</term><term>Immunocompromised Host (MeSH)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Myasthenia Gravis (complications)</term><term>Myasthenia Gravis (drug therapy)</term><term>Myasthenia Gravis (therapy)</term><term>Pandemics (MeSH)</term><term>Plasmapheresis (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Ritonavir (therapeutic use)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Azithromycine (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Diabète de type 2 (complications)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Hypertension artérielle (complications)</term><term>Hypothyroïdie (complications)</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Lopinavir (usage thérapeutique)</term><term>Myasthénie (complications)</term><term>Myasthénie (thérapie)</term><term>Myasthénie (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Plasmaphérèse (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet immunodéprimé (MeSH)</term><term>Sujet âgé (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azithromycin</term><term>Hydroxychloroquine</term><term>Immunoglobulins, Intravenous</term><term>Immunosuppressive Agents</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Diabetes Mellitus, Type 2</term><term>Hypertension</term><term>Hypothyroidism</term><term>Myasthenia Gravis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Myasthenia Gravis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diabète de type 2</term><term>Hypertension artérielle</term><term>Hypothyroïdie</term><term>Immunosuppresseurs</term><term>Infections à coronavirus</term><term>Myasthénie</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Myasthenia Gravis</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Myasthénie</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Myasthénie</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azithromycine</term><term>Hydroxychloroquine</term><term>Immunoglobulines par voie veineuse</term><term>Immunosuppresseurs</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Betacoronavirus</term><term>Female</term><term>Humans</term><term>Immunocompromised Host</term><term>Male</term><term>Pandemics</term><term>Plasmapheresis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Betacoronavirus</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pandémies</term><term>Plasmaphérèse</term><term>Résultat thérapeutique</term><term>Sujet immunodéprimé</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.</p></div><div type="abstract" xml:lang="en"><p><b>CASE DESCRIPTION</b></p><p>We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32731059</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>417</Volume><PubDate><Year>2020</Year><Month>10</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Description of 3 patients with myasthenia gravis and COVID-19.</ArticleTitle><Pagination><MedlinePgn>117053</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(20)30390-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2020.117053</ELocationID><Abstract><AbstractText Label="BACKGROUND">The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.</AbstractText><AbstractText Label="CASE DESCRIPTION">We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.</AbstractText><AbstractText Label="CONCLUSION">Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rein</LastName><ForeName>Netaniel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Netaniel.rein@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haham</LastName><ForeName>Nitzan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: Nitan.haham@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orenbuch-Harroch</LastName><ForeName>Efrat</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romain</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Medical intensive care unit, Jerusalem, Israel. Electronic address: Marcro@hadassah.org.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argov</LastName><ForeName>Zohar</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: zohara@ekmd.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaknin-Dembinsky</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hadassah-Hebrew University Medical Center, Department of Neurology, the Agnes-Ginges Center for Neurogenetics Jerusalem, Israel. Electronic address: marc@gotkine.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010956" MajorTopicYN="N">Plasmapheresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Myasthenia</Keyword><Keyword MajorTopicYN="Y">Neuroimmunology</Keyword><Keyword MajorTopicYN="Y">Neuromuscular</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32731059</ArticleId><ArticleId IdType="pii">S0022-510X(20)30390-7</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.117053</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Rein, Netaniel" sort="Rein, Netaniel" uniqKey="Rein N" first="Netaniel" last="Rein">Netaniel Rein</name></noRegion><name sortKey="Argov, Zohar" sort="Argov, Zohar" uniqKey="Argov Z" first="Zohar" last="Argov">Zohar Argov</name><name sortKey="Gotkine, Marc" sort="Gotkine, Marc" uniqKey="Gotkine M" first="Marc" last="Gotkine">Marc Gotkine</name><name sortKey="Haham, Nitzan" sort="Haham, Nitzan" uniqKey="Haham N" first="Nitzan" last="Haham">Nitzan Haham</name><name sortKey="Orenbuch Harroch, Efrat" sort="Orenbuch Harroch, Efrat" uniqKey="Orenbuch Harroch E" first="Efrat" last="Orenbuch-Harroch">Efrat Orenbuch-Harroch</name><name sortKey="Romain, Marc" sort="Romain, Marc" uniqKey="Romain M" first="Marc" last="Romain">Marc Romain</name><name sortKey="Vaknin Dembinsky, Adi" sort="Vaknin Dembinsky, Adi" uniqKey="Vaknin Dembinsky A" first="Adi" last="Vaknin-Dembinsky">Adi Vaknin-Dembinsky</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32731059
|texte= Description of 3 patients with myasthenia gravis and COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32731059" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |